According to a recent LinkedIn post from Touchlight, the company plans to attend the ASGCT 2026 conference in Boston from May 11–15, with a presence at booth No. 1334. The post indicates that Touchlight aims to engage with gene and cell therapy developers around its cell‑free DNA technologies, including mbDNA and Custom Circles.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights a focus on overcoming limitations associated with plasmid DNA and positioning cell‑free DNA production as a way to accelerate development pipelines. For investors, this visibility at a major scientific conference may support business development opportunities, strengthen Touchlight’s profile in gene and cell therapy manufacturing, and potentially expand its customer base in the DNA supply segment.